Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Postpartum Hemorrhage Management Devices Market Size & Share 2026-2035
Report ID: GMI15213
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Postpartum Hemorrhage Management Devices Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Postpartum Hemorrhage Management Devices Market Size
The postpartum hemorrhage management devices market was valued at USD 1.05 billion in 2025, is projected to reach USD 1.11 billion in 2026, and is expected to expand at a 5.2% CAGR from 2026 to 2035, reaching USD 1.75 billion by 2035.
Postpartum Hemorrhage Management Devices Market Key Takeaways
Market Leader: Organon & Co. led with over 8.1% market share in 2025.
Leading Players: Top 5 players in this market include Organon & Co., CooperSurgical, MedGyn Products, Pregna International, CELOX Medical, which collectively held a market share of 18.5% in 2025.
The postpartum hemorrhage management devices market is being shaped by the need to formalize response pathways for obstetric hemorrhage across increasingly varied delivery settings. Demand is moving beyond emergency availability toward protocol-based stocking, particularly where hospitals are standardizing escalation from uterotonics to mechanical intervention. Revenue growth therefore reflects both procedure volumes and the expanding use of single-use systems within labor-and-delivery preparedness programs.
GMI Analyst View
Our analysis of delivery-side procurement trends and input from industry specialists indicates the postpartum hemorrhage management devices market is on course to reach USD 1.38 billion by 2030, as vacuum-induced tamponade systems extend their hospital formulary presence and programmatic funding commitments in high-burden regions begin converting into device procurement volume at scale-a mid-forecast inflection driven more by international regulatory clearances than by domestic demand dynamics.
Postpartum Hemorrhage Management Devices Market Trends, Growth Drivers & GMI Forecast Outlook
The forecast is underpinned by a durable clinical need for rapid hemorrhage control, but its commercial expression varies sharply by care setting and procurement capacity. Premium device adoption is concentrated in institutions able to fund training, maintain structured response protocols, and absorb single-use consumable costs, while high-burden markets remain dependent on public and programmatic purchasing.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The market is supported by the persistent need for rapid postpartum hemorrhage control, but adoption varies across healthcare systems. Utilization is strongest in facilities with established hemorrhage protocols, trained staff, and procurement resources, while uptake in resource-constrained settings remains influenced by funding, infrastructure, and supply availability.
Vacuum-induced tamponade has strengthened the commercial case for a higher-value intrauterine device category. Its adoption depends on hospitals recognizing a distinct procedural benefit, completing clinician education, and incorporating the system into hemorrhage carts and formulary budgets. As competing formats gain access to more markets, purchasing decisions will increasingly turn on workflow fit, evidence familiarity, and the cost of maintaining ready-to-use inventory.
Policy alignment also expands the addressable institutional market. National protocols that reflect WHO recommendations can move procurement discussions from individual clinician preference to standardized facility readiness. That conversion remains uneven, however, because the pathway from guidance to purchasing depends on local registration, budget authority, staff capability, and supply-chain reliability.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Funding constraints limit the extent to which clinical need can become reliable device purchasing in lower-resource health systems. Public procurement is often episodic, mediated by donors or multilateral programs, and vulnerable to broader health-budget priorities. For manufacturers, this makes the most burden-intensive geographies strategically important but commercially difficult to serve through conventional direct-sales models.
The mismatch between disease burden and facility readiness is equally consequential. Fragmented distribution systems, uneven access to skilled personnel, and gaps in referral infrastructure reduce the number of sites able to deploy advanced intervention devices consistently. Demand therefore concentrates in urban referral hospitals and better-capitalized maternity facilities rather than tracking the full geographic distribution of hemorrhage events.
International expansion is further delayed when regulatory authorization, national guideline adoption, and formulary inclusion proceed on different timelines. Manufacturers may have clinical evidence and commercial intent, but revenue cannot materialize until local pathways permit registration, purchasing, and provider training. This favors organizations with established regulatory capabilities and distributor networks across multiple jurisdictions.
GMI Analyst View
We see the central forecast constraint as commercial access rather than clinical relevance. Mechanical intervention is increasingly recognized within institutional PPH pathways, yet adoption will remain uneven where procurement funding, registration pathways, and clinical training do not mature together. Balloon systems should retain a durable installed-base role, while vacuum-induced systems capture a larger share of new premium-device decisions.
Postpartum Hemorrhage Management Devices Market Segment Analysis
By Product Type
Uterine Tamponade Devices
Uterine tamponade devices held a 63.0% share of the postpartum hemorrhage management devices market in 2025 and are projected to reach USD 1.19 billion by 2035. Their leadership reflects their direct role in standardized hemorrhage escalation pathways, with balloon and vacuum formats addressing different clinical preferences, cost points, and institutional readiness levels. The category's outlook is strengthened by its relevance across high-acuity hospitals and increasingly protocolized maternity settings.
Balloon Tamponade Systems
Balloon tamponade systems generated USD 399 million in 2025 and are projected to account for a 37.1% share of the global market by 2035. The segment retains broad clinical familiarity, a substantial evidence base, and applicability across vaginal and cesarean delivery contexts. Its future role is less about displacement than dependable volume support, particularly where providers prioritize established technique, lower acquisition cost, and straightforward deployment.
Vacuum-Induced Tamponade
Vacuum-induced tamponade held a 25.0% share of the global market in 2025 and is expected to expand at a 7.5% CAGR from 2026 to 2035. Growth is being supported by hospital interest in interventions designed to promote physiological uterine contraction while reducing the need for prolonged escalation. The segment's commercial potential depends on new market clearances, provider confidence, reimbursement conditions, and the ability of suppliers to convert clinical awareness into formulary adoption.
Non-Pneumatic Anti-Shock Garments
NASG generated USD 74 million in 2025 and are forecast to grow at a 3.6% CAGR from 2026 to 2035. Their role is distinct from intrauterine interventions, centering on temporary stabilization and transport in resource-constrained environments. Demand remains tied to humanitarian, public-health, and programmatic procurement, which creates a durable need but limits exposure to the premium hospital purchasing dynamics supporting higher-growth tamponade categories.
Prefilled Uterotonic Injection Systems
Prefilled uterotonic injection systems represented a 30.0% share of the market in 2025 and are projected to reach USD 453 million by 2035. Their adoption is supported by readiness, dose standardization, and workflow convenience, especially in facilities seeking rapid access to treatment supplies. However, procurement sensitivity, cold-chain requirements, and competition from conventional pharmaceutical presentations constrain their ability to match the momentum of mechanical tamponade technologies.
By Patient Type
Primary PPH
Primary PPH generated USD 913 million in 2025 and is projected to represent an 85.0% share of the market by 2035. This segment dominates because most device use occurs during or shortly after delivery, when clinicians are managing acute blood loss in a monitored institutional setting. Its scale makes labor-and-delivery protocol design, staff preparedness, and early recognition of uterine atony central determinants of device utilization.
Secondary PPH
Secondary PPH accounted for a 13.0% share of the market in 2025 and is anticipated to grow at a 6.7% CAGR from 2026 to 2035. The segment benefits from greater clinical recognition of delayed hemorrhagic events and from the gradual extension of postpartum monitoring across non-acute settings. Suppliers with portable, workflow-adaptable formats may be better positioned as outpatient and ambulatory care models evolve.
By End Use
Hospitals
Hospitals generated USD 756 million in 2025 and are expected to account for a 68.1% share of the global market by 2035. They remain the core purchasing channel because complex PPH cases require rapid access to multidisciplinary care, surgical escalation, blood products, and intensive monitoring. Group purchasing arrangements and mandated obstetric readiness standards also create recurring demand for stocked devices and associated consumables.
Maternity & Birthing Centers
Maternity and birthing centers held a 16.0% market share in 2025 and are projected to reach USD 315 million by 2035. Channel expansion depends on whether accreditation and referral frameworks support broader use of hemorrhage-management protocols outside acute hospitals. Balloon tamponade and prefilled systems are particularly relevant where providers need ready access to intervention tools but must also maintain clear escalation pathways for severe cases.
Ambulatory Surgical Centers
Ambulatory surgical centers accounted for an 8.0% share of the market in 2025 and are forecast to expand at a 7.6% CAGR from 2026 to 2035. Their growth reflects incremental opportunities as lower-complexity obstetric services move into cost-sensitive outpatient environments. Progress will depend on local eligibility rules, reimbursement support, emergency-transfer readiness, and the suitability of single-use device kits for facilities with limited inventory capacity.
GMI Analyst View
We expect product-mix change to occur through new purchasing decisions rather than wholesale replacement of established balloon systems. Hospitals entering or updating the category are more likely to assess vacuum technologies alongside legacy formats, while ambulatory and maternity settings will favor products that fit their staffing, referral, and inventory constraints. The most attractive segments are those aligned with clearly defined clinical workflows.
Postpartum Hemorrhage Management Devices Market Regional Analysis
North America Postpartum Hemorrhage Management Devices Market Analysis
The postpartum hemorrhage management devices market in North America held a 32.0% share in 2025 and is projected to reach USD 525 million by 2035. The region benefits from mature hospital purchasing systems, high protocol penetration, and strong reimbursement support for advanced obstetric care. Its commercial profile favors premium single-use devices, established clinical training, and manufacturers able to serve large integrated delivery networks.
U.S.
The U.S. generated USD 305 million in 2025 and is expected to account for 89.5% of North American revenue by 2035. Demand is supported by high adoption within large birthing hospitals, robust clinical quality initiatives, and a comparatively developed reimbursement environment. The market remains a critical proving ground for new PPH device formats because hospital systems can integrate training, procurement, and outcome-monitoring processes at scale.
Canada
Canada accounted for a 9.2% share of North American revenue in 2025 and is forecast to grow at a 5.9% CAGR from 2026 to 2035. The country provides an important adjacent expansion opportunity for suppliers pursuing North American scale beyond the U.S. Health Canada authorization and subsequent commercial availability of the Jada System broadened the vacuum-induced tamponade category available to Canadian birthing hospitals [7]Organon Canada. "News Release: Organon Canada Announces Availability of the JADA® System, a Medical Device Intended to Control and Treat Postpartum Hemorrhage." organon.com.
Europe Postpartum Hemorrhage Management Devices Market Analysis
Europe generated USD 284 million in 2025 and is expected to represent a 24.0% market share by 2035. Regional demand is shaped by national procurement structures, payer decisions, and uneven adoption of standardized obstetric hemorrhage pathways. While regulatory access can be regionalized, commercial conversion remains dependent on country-specific health technology assessment, hospital budgets, and clinical practice patterns.
Germany
Germany generated USD 50 million in 2025 and is expected to account for 18.1% of European revenue by 2035. High-volume obstetric centers and university hospitals support demand for evidence-backed tamponade and injection systems. Purchasing-group influence and insurer expectations make clinical familiarity and demonstrated workflow value important to supplier success.
UK
The UK represented a 16.9% share of the European market in 2025 and is projected to generate USD 72 million by 2035. NHS governance and care-bundle implementation provide a structured route for translating clinical protocols into standardized device availability. Midwife-led settings can expand demand where they are equipped with defined escalation procedures and supply-chain access.
France
France generated USD 38 million in 2025 and is forecast to grow at a 4.0% CAGR from 2026 to 2035. Centralized purchasing and formal reimbursement mechanisms place a premium on evidence, procurement fit, and alignment with maternal-safety priorities. Adoption is likely to remain strongest in tertiary obstetric facilities where protocol implementation and staff training can be maintained consistently.
Italy
Italy accounted for 10.2% of European revenue in 2025 and is projected to reach USD 42 million by 2035. Geographic variation in hospital infrastructure and regional health administration creates uneven penetration across the country. Suppliers must navigate decentralized purchasing priorities while demonstrating value to larger obstetric centers that can standardize device use.
Spain
Spain held a 9.5% share of European revenue in 2025 and is expected to grow at a 3.5% CAGR from 2026 to 2035. Budget pressure and procurement fragmentation across autonomous communities constrain adoption of premium systems. Greater clinical interest in standardized PPH management can support demand, but conversion will depend on local budget decisions and practical implementation capacity.
Netherlands
The Netherlands generated USD 18 million in 2025 and is expected to represent 6.7% of European revenue by 2035. Its integrated midwifery-hospital referral model supports broader preparedness across delivery settings than in many comparable markets. Consistent safety initiatives and coordinated care pathways favor reliable device stocking, particularly where community and hospital services share escalation protocols.
Asia Pacific Postpartum Hemorrhage Management Devices Market Analysis
The postpartum hemorrhage management devices market in Asia Pacific held a 25.0% share in 2025 and is projected to reach USD 490 million by 2035. Growth is supported by institutional delivery expansion, improving hospital infrastructure, and wider health-insurance coverage across middle-income markets. The region's opportunity is substantial but heterogeneous, with advanced urban facilities adopting premium technologies while lower-resource sites continue to require cost-sensitive formats and public procurement support.
China
China accounted for 31.9% of Asia Pacific revenue in 2025 and is projected to reach USD 172 million by 2035. Hospital modernization and procurement reform are reshaping how obstetric intervention products are evaluated and purchased in high-capacity urban facilities. Large absolute birth volumes continue to support demand despite demographic pressures, while supplier access depends on navigating local registration and purchasing systems.
India
India generated USD 74 million in 2025 and is anticipated to grow at a 6.3% CAGR from 2026 to 2035. Rising institutional delivery rates create an expanding platform for device demand, although purchasing remains highly segmented between private hospital chains and public-sector programs. Premium tamponade systems are likely to gain initial traction in urban facilities, while lower-cost formats remain more relevant to broader public-health access.
Japan
Japan generated USD 42 million in 2025 and is expected to account for 14.7% of Asia Pacific revenue by 2035. The market is characterized by advanced institutional care and high standards for device registration, but limited underlying delivery-volume expansion. Suppliers must therefore compete on clinical differentiation, local regulatory capability, and fit within a mature hospital environment.
Australia
Australia accounted for an 8.0% share of Asia Pacific revenue in 2025 and is projected to reach USD 33 million by 2035. The market offers a favorable setting for adoption of advanced hemorrhage-management devices through public and private birthing hospitals. Commercial uptake will be influenced by formulary review cycles, clinician education, and the pace at which institutions incorporate newer intervention formats into established response protocols.
South Korea
South Korea held a 6.1% share of Asia Pacific revenue in 2025 and is forecast to grow at a 5.8% CAGR from 2026 to 2035. Its concentrated hospital infrastructure and active academic obstetrics community can support evidence-led adoption after local registration. Market development is likely to favor suppliers with strong regulatory execution and the ability to engage specialist clinicians at leading urban institutions.
Latin America Postpartum Hemorrhage Management Devices Market Analysis
Latin America generated USD 95 million in 2025 and is expected to grow at a 6.3% CAGR from 2026 to 2035. The region is benefiting from stronger institutional-delivery coverage, expanding social insurance, and broader clinical awareness of structured PPH intervention. Commercial opportunities are concentrated in larger national markets, although import costs, registration requirements, and public-sector procurement cycles can affect supplier access.
Brazil
Brazil generated USD 42 million in 2025 and is projected to represent 42.3% of Latin American revenue by 2035. Its scale reflects the combined influence of public-system and private-sector delivery volumes. Import duties and distribution complexity raise the importance of local partnerships, while the adoption of standardized obstetric emergency protocols can support demand for tamponade and injection systems.
Mexico
Mexico accounted for 26.3% of Latin American revenue in 2025 and is anticipated to grow at a 6.5% CAGR from 2026 to 2035. Public purchasing through social-security institutions provides a meaningful demand channel alongside private hospitals. Its medical-device registration environment and substantial institutional delivery base make Mexico an important entry market for suppliers seeking regional commercial reach.
Argentina
Argentina held a 10.5% share of Latin American revenue in 2025 and is projected to reach USD 19 million by 2035. Demand is affected by import constraints and economic volatility, which can make procurement cycles less predictable. Public hospitals remain particularly relevant for lower-cost and programmatically funded device categories, while private providers offer a more limited premium-device opportunity.
Middle East & Africa (MEA) Postpartum Hemorrhage Management Devices Market Analysis
MEA generated USD 74 million in 2025 and is expected to grow at a 6.6% CAGR from 2026 to 2035. The region contains markedly different commercial environments: Gulf markets support premium hospital purchasing, while much of sub-Saharan Africa relies on public, donor, and humanitarian procurement. International programs addressing PPH management can expand access to lower-cost intervention categories, but geographic coverage remains limited relative to need [6]UNFPA. "Joint UNFPA-Unitaid Venture Backed by Major EU Funding Aims to Eliminate the Leading Cause of Mothers Dying in Childbirth in Africa." unfpa.org.
South Africa
South Africa accounted for 20.3% of MEA revenue in 2025 and is projected to reach USD 26 million by 2035. Its developed private and public hospital sectors support a wider range of PPH interventions than many neighboring markets. Future demand will be influenced by procurement reform, tertiary-care capacity, and the ability to maintain consistent stocking across referral facilities.
Saudi Arabia
Saudi Arabia generated USD 21 million in 2025 and is expected to account for 28.6% of MEA revenue by 2035. Hospital modernization and government procurement create a favorable setting for advanced obstetric devices. International manufacturers with local distribution relationships are well positioned to participate in tender-led purchasing by major maternity hospitals.
UAE
The UAE represented 21.6% of MEA revenue in 2025 and is anticipated to grow at a 6.1% CAGR from 2026 to 2035. High institutional birth rates, concentrated urban healthcare infrastructure, and a sizeable private hospital sector support predictable device demand. Its regional distribution role further increases the strategic importance of in-country registration and commercial partnerships.
GMI Analyst View
We view regional performance as a balance between purchasing power and clinical need. North America and higher-income Asia Pacific markets will continue to support premium-device adoption, whereas lower-income markets will rely more heavily on affordability, programmatic funding, and workforce readiness. The most durable international strategies will combine high-value hospital channels with locally appropriate access models.
Postpartum Hemorrhage Management Devices Market Share & Competitive Landscape
The postpartum hemorrhage management devices market share landscape is fragmented, with the five leading companies collectively accounting for 18.5% of the market in 2025. Competition differs materially by product category: premium vacuum systems compete through clinical workflow and hospital access, balloon tamponade suppliers compete on familiarity and procurement fit, and lower-cost products depend more heavily on distribution reach and public-sector positioning.
Organon & Co.
Organon held an 8.1% market share in 2025, supported by the Jada System's position in vacuum-induced tamponade. The system has reached more than 136,000 patients in more than 20 countries [4]Organon. "Organon Announces Agreement to Divest Its JADA® System for Up to $465 Million to Laborie." organon.com. Organon's competitive relevance through the base year reflects its U.S. commercial execution, provider engagement, and ability to build a differentiated category around a procedure-oriented hospital product.
CooperSurgical
CooperSurgical held a 5.5% market share in 2025. Its Bakri Postpartum Balloon gives the company a strong position in a clinically familiar category where hospital purchasing groups, established provider experience, and a broad obstetrics portfolio can reinforce account access. Its competitive strength is tied to the continued importance of balloon tamponade in standard hemorrhage-response inventories.
MedGyn Products
MedGyn Products held a 2.1% market share in 2025. The company competes through value-oriented intrauterine balloon and intervention-consumable offerings suited to international hospital markets. Its positioning is relevant in procurement environments where broad regulatory coverage, price discipline, and distributor reach matter more than a single premium technology platform.
Pregna International
Pregna International serves reproductive-health and uterine-balloon demand in markets where government, nongovernmental, and programmatic purchasing can determine category access. Its emerging-market orientation provides an advantage where lower-cost product design, local registration, and distributor relationships are more decisive than premium hospital branding.
CELOX Medical
CELOX Medical participates through hemostatic consumables relevant to obstetric hemorrhage management. Its crossover from wound-care applications illustrates the wider clinical interest in adjunctive hemorrhage-control products, although its role differs from suppliers focused primarily on intrauterine device platforms.
Other Competitors
Other participants include 3rd Stone Design, Becton, Dickinson and Company, SINAPI, STERIMED, Utah Medical Products, and ZOEX NIASG. Competitive intensity is sustained by localized procurement preferences, variable regulatory requirements, and the coexistence of premium, value-tier, and programmatic demand channels. Manufacturers able to pair clinical training with dependable distribution are better placed to translate product availability into recurring institutional use.
Recent Industry Developments
Organon announced an agreement in November 2025 to divest the Jada System to Laborie Medical Technologies for up to USD 465 million, including USD 440 million payable at closing and up to USD 25 million contingent on revenue performance [4]Organon. "Organon Announces Agreement to Divest Its JADA® System for Up to $465 Million to Laborie." organon.com. The planned transaction included the expected transfer of approximately 100 employees supporting the Jada commercial and clinical organization. It signals a potential shift in the category's commercial ownership toward a medical-technology platform with international expansion capability.
Organon Canada announced commercial availability of the Jada System in September 2024 following Health Canada device authorization earlier that year [7]Organon Canada. "News Release: Organon Canada Announces Availability of the JADA® System, a Medical Device Intended to Control and Treat Postpartum Hemorrhage." organon.com. The launch extended access to vacuum-induced tamponade in Canada and illustrates the sequential country-by-country market-entry pattern facing manufacturers of newer obstetric intervention technologies.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →